Christian Rohlff
Chief Executive Officer Oxford Biotherapeutics
Christian has served as CEO of Oxford BioTherapeutics since founding the company and acquiring its core technology, OGAP®-Verify. He brings more than 30 years of international experience in oncology drug discovery, platform driven target identification, and strategic partnering. He has a proven track record of building and scaling oncology businesses from discovery through clinical development, creating value through high quality pharmaceutical partnerships and capital efficient growth.
Christian founded and built OBT into a leading oncology company specialising in proteomics driven target discovery for antibody-based therapeutics. He established OGAP®-Verify, the world’s largest oncology focused proteomics platform, enabling the systematic discovery and validation of novel cancer targets. Under his leadership, OBT has evolved from a discovery start up into a partner validated, clinical stage oncology company with expanding preclinical and development capabilities. He has also led the establishment of multiple strategic collaborations with leading pharmaceutical companies, including Bristol Myers Squibb, Roche, GSK, Boehringer Ingelheim, and ImmunoGen, spanning ADCs, T-cell engagers, and antibody platforms.
Seminars
- Understanding the 2027 ADC landscape and how the bar has been raised to develop and deliver ADCs with meaningful patient impact
- Outlining the future opportunities and applications on the horizon for ADCs to achieve target differentiation and clinical safety
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
This workshop will focus on improving translatability of pre-clinical findings to first-in human studies that maximise learning while ensuring patient safety. It will be an opportunity to discuss back-translation strategies to inform next-generation ADC design.
Key Questions:
- Which ADC designs demonstrate the best clinical efficacy and outcomes by overcoming resistance challenges?
- How do we establish human dose projections from pre-clinical studies?
- What can we learn from clinical failures to improve current ADC designs?
